Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant

Haematologica

Volumn 86, Issue 6, 2001, Pages 618-623

  Dotti, G ^a   Rambaldi, A ^a   Fiocchi, R ^a   Motta, T ^a   Torre, G ^a   Viero, P ^a   Gridelli, B ^a   Barbui, T ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Allogeneic bone marrow transplant; Immunosuppression; Immunotherapy; PTLD; Rituximab; Solid organ transplant

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; LIVER TRANSPLANTATION; MALE; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; ORGAN TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0034961829     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop
2. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients
3. Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant
4. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity?
5. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
6. Aggressive treatment for postcardiac transplant lymphoproliferation
7. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
8. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
9. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
10. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
11. Humanised anti CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorders: A retrospective analysis on 32 patients
12. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
13. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled (PAP) procedures
14. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients
15. Classification of the posttransplant lymphoproliferative disorders: From the past to the present
16. Primary effusion lymphoma after heart transplantation: A new entity associated with human herpesvirus-8
17. Detection of immunoglobulin heavy-chain gene rearrangements by Southern blot analysis: Recommendations for optimal results
18. Toxicity and response criteria of the Eastern Cooperative Oncology Group
19. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy
20. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
21. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
22. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting